Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.02 USD
Change Today -0.0084 / -27.54%
Volume 95.3K
As of 5:20 PM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

gelstat corp (GSAC) Snapshot

Open
$0.03
Previous Close
$0.03
Day High
$0.03
Day Low
$0.02
52 Week High
07/8/14 - $0.08
52 Week Low
12/11/14 - $0.02
Market Cap
2.8M
Average Volume 10 Days
7.1K
EPS TTM
$-0.02
Shares Outstanding
127.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GELSTAT CORP (GSAC)

Related News

No related news articles were found.

gelstat corp (GSAC) Related Businessweek News

No Related Businessweek News Found

gelstat corp (GSAC) Details

GelStat Corporation operates as a consumer healthcare company. The company engages in the development and marketing of over-the-counter and other non-prescription consumer health care products. It offers Gelstat Migraine, a patented homeopathic drug designed to provide acute relief from migraine and migraine-like headaches; and Gelstat Sleep, a sleep aid product. It is also developing various healthcare products that address consumer markets. The company provides its products directly, as well as through independent retailers and pharmacies. GelStat Corporation also sells its products through its Website gelstat.com. The company is based in Palm City, the United States.

gelstat corp (GSAC) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

gelstat corp (GSAC) Key Developments

GelStat Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Revenue Guidance for 2015

GelStat Corporation reported earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenue of $750,218 up 38% from $542,477 in the prior quarter. Net losses were $178,805 down 61% from $457,935 in the prior quarter. For the full year, the company reported revenue of $1,312,675 and gross profit of $221,860. The company provided revenue guidance for 2015. Leveraging the proprietary manufacturing process to make chewing gum and lozenges incorporating dietary supplement active ingredients, the company expects revenue for 2015 to be in the range of $3.0 to $5.0 million. This revenue growth is expected to come from the continuation of existing products manufacture for its customers as well as from new proprietary and branded product launches. One new product in final stages of retail distribution approval alone could generate revenue of $500,000 or more in the second or third quarter of 2015.

GelStat Corp. Announces Consolidated Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Revenue Guidance for 2015

GelStat Corp. announced consolidated revenue results for the fourth quarter and full year ended December 31, 2014. The company generated consolidated revenue in excess of $750,000 for the fourth quarter. The company generated consolidated revenue in excess of $1.3 million for the full year ended December 31, 2014 led by its wholly owned subsidiary Mastix Medica. For 2015, the company expects growth to continue and revenues to be in the $4.5 to $5.5 million range.

GelStat Corp. to Report Q4, 2014 Results on Mar 31, 2015

GelStat Corp. announced that they will report Q4, 2014 results at 1:41 PM, GMT Standard Time on Mar 31, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GSAC:US $0.02 USD -0.0084

GSAC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bristol-Myers Squibb Co $67.50 USD +0.02
View Industry Companies
 

Industry Analysis

GSAC

Industry Average

Valuation GSAC Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GELSTAT CORP, please visit www.gelstat.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.